PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22031231-0	2012	Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.	Vinorelbine	83-94	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	4-9	
23856142-14	2013	CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine.	Vinorelbine	298-307	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	132-137	
22960937-15	2012	CONCLUSION: Combined negative ERCC1 and class III beta-tubulin immunostaining is associated with significantly prolonged PFS and OS in MPM patients receiving cisplatin-vinorelbine therapy.	Vinorelbine	168-179	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35	
22031231-1	2012	INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.	Vinorelbine	195-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	39-84	
22031231-1	2012	INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial.	Vinorelbine	195-206	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	86-91	
22031231-13	2012	CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation.	Vinorelbine	75-86	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	105-110	
21357891-7	2011	Retrospective, unplanned analysis of excision repair cross complementation group 1 (ERCC1) and betatubulin III upregulation demonstrated poorer outcome in NSCLC patients treated with platinum-doublets and vinorelbine-based chemotherapy, respectively.	Vinorelbine	205-216	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-82	
21357891-7	2011	Retrospective, unplanned analysis of excision repair cross complementation group 1 (ERCC1) and betatubulin III upregulation demonstrated poorer outcome in NSCLC patients treated with platinum-doublets and vinorelbine-based chemotherapy, respectively.	Vinorelbine	205-216	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	84-89	
20082278-2	2009	The purpose of this study was to investigate the prognostic value of multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance-related protein (LRP), and excision repair cross-complementing 1 (ERCC1) in NSCLC patients receiving cisplatin-based adjuvant chemotherapy (cisplatin plus vinorelbine or gemcitabine) after tumor resection.	Vinorelbine	320-331	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	231-236	
20627363-2	2011	In this study, we assessed whether the presence of polymorphisms in ERCC1, XPD, RRM1 and MDR1 genes can affect the efficacy and the tolerability of cisplatin and vinorelbine in NSCLC patients.	Vinorelbine	162-173	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	68-73	
21885003-8	2008	A phase II study demonstrated the feasibility of combining carboplatin, gemcitabine, docetaxel, and vinorelbine according to ERCC1 and ribonucleotide reductase subunit M1 expression levels.	Vinorelbine	100-111	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	125-130